DMC Global reported a 14% increase in third-quarter sales to $172.8 million and a net income of $9.7 million, reversing a loss from the prior year. Adjusted EBITDA rose 59% excluding $5.4 million in tariff refunds, reflecting improved operational efficiency and cost-saving measures across its business segments. The company expects Q4 sales between $154 million and $164 million amid ongoing market challenges and plans to maintain focus on cost optimization and market share growth. Net debt fell to its lowest since a major acquisition in 2021, strengthening its financial position.
DMC Global's third-quarter financial results provide context for readers following industrials. As of Oct 28, 2026 03:12 WIB, among 135 priced Industrials-sector US stocks tradable on Pluang, 84 rose and 51 fell. Notable movers include Boeing Co (BA) at USD 168.05 with a 1-day change of -10.76% and Pluang order activity of 28% Sell / 72% Buy, Intuitive Machines (LUNR) at USD 11.50 with a 1-day change of +9.73% and Pluang order activity of 91% Sell / 9% Buy, and American Superconductor Corporation (AMSC) at USD 27.66 with a 1-day change of +8.90%.
The global drone defense system market is projected to grow from $4.72 billion in 2025 to $18.19 billion by 2030, driven by increasing unauthorized drone incidents and demand for advanced detection and countermeasure technologies. Growth is fueled by...
Eli Lilly has outpaced Novo Nordisk in the GLP-1, obesity, and Type 2 Diabetes market, achieving a $1.21 trillion valuation. While Novo Nordisk's share price has fallen back after earlier gains and revenue growth remains flat, its management's strate...
argenx SE announced it will stop its Phase 3 UNITY study of efgartigimod subcutaneous for moderate-to-severe Sjögren's disease after an independent committee found the trial unlikely to meet its primary goal. This decision caused the company's stock ...
Pomerantz LLP is investigating DaVita Inc. for potential securities fraud following a sharp stock price drop triggered by a new U.S. federal strategy targeting the dialysis market. The Department of Health and Human Services announced a plan to incre...
Pomerantz LLP is investigating ClearPoint Neuro and its executives for possible securities fraud following a significant stock price drop. The decline occurred after ClearPoint's partner, uniQure, announced that their Huntington's disease treatment f...
